{"title":"转移性葡萄膜黑色素瘤完全缓解纳武单抗:1例报告","authors":"Melih Filiz","doi":"10.52768/2833-2725/1090","DOIUrl":null,"url":null,"abstract":"Introduction: Uveal Melanoma (UM) is a rare subtype of melanoma that progresses to metastatic disease in more than 50% of patients [1]. After metastasis develops, the average survival is between 4-15 months [2].","PeriodicalId":108891,"journal":{"name":"Open Journal of Clinical and Medical Images","volume":"39 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Metastatic uveal melanoma complete response with nivolumab: A case report\",\"authors\":\"Melih Filiz\",\"doi\":\"10.52768/2833-2725/1090\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Uveal Melanoma (UM) is a rare subtype of melanoma that progresses to metastatic disease in more than 50% of patients [1]. After metastasis develops, the average survival is between 4-15 months [2].\",\"PeriodicalId\":108891,\"journal\":{\"name\":\"Open Journal of Clinical and Medical Images\",\"volume\":\"39 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Journal of Clinical and Medical Images\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.52768/2833-2725/1090\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Journal of Clinical and Medical Images","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52768/2833-2725/1090","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Metastatic uveal melanoma complete response with nivolumab: A case report
Introduction: Uveal Melanoma (UM) is a rare subtype of melanoma that progresses to metastatic disease in more than 50% of patients [1]. After metastasis develops, the average survival is between 4-15 months [2].
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
